Spravato® (Esketamine) Therapy
FDA-approved nasal spray for treatment-resistant depression.
Start Online Intake
60-sec Video
Most major insurers cover Spravato®
See accepted plans ›
FDA-Indicated
TR-Depression
TR-Depression
Clinic-Only
2-hr Monitoring
2-hr Monitoring
Rapid Relief
24 hrs for some
24 hrs for some
Insurance Friendly
Benefits in 24 hrs
Benefits in 24 hrs
Spravato® in Action
How Spravato® Works
Esketamine is an NMDA-receptor antagonist (different from SSRIs/SNRIs). Peak effect 20–40 min; half-life 7–12 hrs. Many patients notice improvement within 24 hrs.
- Induction (Weeks 1-4): 56 mg on Day 1 → 56 mg or 84 mg twice weekly.
- Maintenance: 56 mg or 84 mg weekly or every other week.
- 5-min pause between devices for absorption.
Is Spravato® Right for You?
Ideal Candidates
- Failed ≥ 2 antidepressant trials
- Severe symptoms or suicidal thoughts
- Prefer supervised nasal spray vs. IV ketamine/ECT
Safety Checklist
- Common: sedation, dissociation, transient ↑ BP
- Rare: hypertensive crisis (pre-screened)
- No driving until next day — arrange a ride
- Dispensed only in REMS-certified centers
Evidence & Outcomes
In pivotal trials, Spravato® plus an oral antidepressant reduced depressive symptoms and cut relapse risk in maintenance studies. It offers fast relief when standard options fail learn more ›.
Start Secure Intake
📄 Full Spravato® Fact Sheet (PDF)
Disclaimer: Educational only — not medical advice. All treatments follow FDA REMS guidelines in our certified clinic.